Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eeyarestatin-1 (EerI) is a small molecule inhibitor of endoplasmic reticulum-associated degradation (ERAD) and protein translocation. It acts by targeting the AAA+ ATPase p97 (also known as valosin-containing protein, VCP) and the Sec61 translocon complex. By inhibiting p97-associated deubiquitinating enzymes (such as ataxin-3) and blocking Sec61-mediated protein translocation across the ER membrane, Eeyarestatin-1 disrupts ER proteostasis, induces severe endoplasmic reticulum stress, and activates the unfolded protein response (UPR). This leads to the upregulation of pro-apoptotic factors like NOXA and ATF4, preferentially inducing cell death in cancer cells. Eeyarestatin-1 is widely utilized as a chemical biology tool to study ER homeostasis, protein retrotranslocation, and intracellular trafficking pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eeyarestatin-1.